Farxiga Approval Expands Use to More Patients With Heart Failure
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
A recent study found a racial disparity in the use of guideline-concordant treatment for metastatic prostate cancer.
A study was conducted to determine the relationship between changes in NT-proBNP levels and risk for heart failure and death.
Researchers sought to describe the prevalence of VHD stages among older adults; determine the prognostic relevance of VHD stages for incidence CVDs; and characterize the progression in VHD stages over 6 years in late life.
Histologic lesions in the kidney may reflect systemic processes that lead to cardiovascular events, according to investigators.
Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for SC administration via an on-body infusor for outpatient self-administration.
The FDA is requiring the Company to conduct an additional clinical trial evaluating omecamtiv mecarbil for HFrEF.
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
The American Heart Association has issued a statement regarding HF patient’s use of over-the-counter medications and supplements.
The application is supported by data from the phase 3 EMPEROR-Preserved trial.